Skip to main content
Premium Trial:

Request an Annual Quote

Pharmacia & Upjohn Plans New Research Center Construction

Premium

STOCKHOLM, Sweden--Pharmacia & Upjohn is moving forward on plans for construction of a $137 million research center here. Research and development president Goran Ando said the center will help the company achieve the critical mass necessary to achieve its goal of discovering 10-12 new candidate drugs per year.

Pharmacia & Upjohn intends to make this center the world leader in metabolic disease research and innovation, Ando said. Last year, with the Karolinska Institute, the company established a Center for Genomics Research as part of the its effort to seek partnerships with the academic research community in the area of molecular genetics.

Filed under

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.